- Report
- March 2024
- 188 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- April 2024
- 89 Pages
Global
From €5405EUR$5,600USD£4,637GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Report
- August 2023
- 279 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- November 2023
- 179 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- September 2018
- 73 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- August 2022
- 70 Pages
Global
From €4778EUR$4,950USD£4,098GBP
- Report
- March 2022
- 166 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Drug Pipelines
- March 2022
- 83 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
Amyloidosis is a rare endocrine and metabolic disorder caused by the accumulation of abnormal proteins in the body's organs and tissues. Treatment for amyloidosis typically involves a combination of drugs, including chemotherapy, corticosteroids, and immunosuppressants. The amyloidosis drug market is expected to grow in the coming years due to the increasing prevalence of the disease and the development of new drugs.
The amyloidosis drug market is highly competitive, with a number of companies developing and marketing drugs for the treatment of the disease. Some of the major players in the market include Pfizer, Novartis, Sanofi, Merck, and Johnson & Johnson. These companies are focusing on developing new drugs and expanding their product portfolios to meet the growing demand for amyloidosis treatments. Show Less Read more